| Moranne, Olivier |
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
|
|
| Active, not recruiting | 3 | 1083 | Europe, Canada, US, RoW | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 12/24 | 02/25 | | |
| Recruiting | 3 | 272 | Europe | 56 days of weight-adjusted L-Carnitine treatment, 10 days of intravenous placebo (isotonic saline) | Centre Hospitalier Universitaire de Nīmes | Severe Sepsis, Shock, Septic, Acute Kidney Injury | 05/25 | 05/26 | | |
RIGA, NCT05329090: Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis |
|
|
| Recruiting | 3 | 72 | Europe | Rituximab Injection, Rixathon, Truxima, placebo, NaCl | Hopital Foch, Ministry of Health, France | IgA Vasculitis | 03/25 | 03/26 | | |
RENATO, NCT05946564: A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - Trial |
|
|
| Recruiting | 3 | 126 | Europe | Pioglitazone (ACTOS®), Placebo of Pioglitazone | Assistance Publique - Hôpitaux de Paris, Ministry of Health, France | ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic Glomerulonephritis | 04/27 | 10/27 | | |
MASTER-ANCA, NCT03323476: Maintaining or Stopping Immunosuppressive Therapy in Patients with ANCA Vasculitis and End-stage Renal Disease |
|
|
| Recruiting | 3 | 136 | Europe | Discontinuation (or not initiation) of Immunosuppressive Therapy, Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl® | Centre Hospitalier Departemental Vendee | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, End Stage Renal Disease | 03/31 | 03/31 | | |
NCT03804359: Personalized Medicine for Membranous Nephropathy |
|
|
| Recruiting | 2 | 64 | Europe | Rituximab | Centre Hospitalier Universitaire de Nice | Idiopathic Membranous Nephropathy | 09/23 | 09/23 | | |
TRIBECA, NCT04629144 / 2020-004519-29: Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis) |
|
|
| Recruiting | 2 | 48 | Europe | Belimumab, Placebo | Assistance Publique - Hôpitaux de Paris, GSK | Vasculitis, Cryoglobulinemia | 04/25 | 10/25 | | |
| Recruiting | N/A | 80 | Europe | | Central Hospital, Nancy, France, Agence de La Biomédecine, CIC 1433 EC CHRU de Nancy, Association France REIN | Patients Reported Outcomes | 09/23 | 11/23 | | |
WARNING KD, NCT05033652: Impact on Mortality of Screening for Kidney Disease Associated With a Specialized Intervention During Hospitalization in a Territorial Hospital Trust |
|
|
| Recruiting | N/A | 1680 | Europe | WARNING KD | Centre Hospitalier Universitaire de NÄ«mes | Acute Kidney Injury, Chronic Kidney Diseases | 12/23 | 12/24 | | |
APHERCOAG, NCT06571552: Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study. |
|
|
| Recruiting | N/A | 6 | Europe | Single Plasma Exchange followed by Double Filtration Plasmapheresis | Centre Hospitalier Universitaire de Nīmes | Hyperfibrinogenemia, Hemostatic Disorder | 06/25 | 06/26 | | |
MRC-Gard, NCT02938611: Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France |
|
|
| Recruiting | N/A | 3375 | Europe | | Centre Hospitalier Universitaire de Nīmes | Renal Insufficiency, Chronic | 12/25 | 12/25 | | |
| Recruiting | N/A | 3000 | Europe | No intervention | European Georges Pompidou Hospital, Oscar - Filière Santé Maladies Rares | Hypoparathyroidism | 09/30 | 09/31 | | |
| Beaume, Julie |
| Recruiting | N/A | 3000 | Europe | No intervention | European Georges Pompidou Hospital, Oscar - Filière Santé Maladies Rares | Hypoparathyroidism | 09/30 | 09/31 | | |
